(lp0
S"Arca Biopharma Inc  Announces The Enrollment Of The Randomized ... Journal Transcript - Mar 8, 2017 Arca Biopharma Inc , announced that 175 patients have been randomized into GENETIC-AF. It's a unique design Phase 2B/3 clinical trial for the evaluation of a new drug - Gencaro (bucindolol hydrochloride, a beta blocker and a mild&nbsp;..."
p1
aS'ARCA biopharma Announces Fiscal Year 2016 Financial Results and Provides ... Yahoo Finance - Mar 21, 2017 ARCA biopharma, Inc. , a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the year ended December 31, 2016, and&nbsp;...ARCA biopharma, Inc.  Files An 8-K Results of Operations and ... - Market Exclusive'
p2
aS'Arca Biopharma Inc  Announces 175th Patient Randomized into the ... Journal Transcript - Mar 7, 2017 Arca Biopharma Inc , a biopharmaceutical company that develops genetically-oriented therapies meant for treatment of cardiovascular diseases has announced randomizing the GENETIC-AF.'
p3
aS'Insider Buying: Arca Biopharma Inc  Director Buys 25000 Shares of Stock Sports Perspectives - 3 hours ago Arca Biopharma logo Arca Biopharma Inc  Director Robert E. Conway bought 25,000 shares of Arca Biopharma stock in a transaction that occurred on Friday, March 24th.Near-Term, Can This Stock Move the Needle: ARCA biopharma, Inc.  - Morgan Research'
p4
aS'Why Arca Biopharma Is A Buy Seeking Alpha - Jan 14, 2014 Arca Biopharma  is a pre-revenue company that has patents through 2029 covering the drug Gencaro .'
p5
aS"Insider Trading Activity Arca Biopharma Inc   insider Sold 720 ... Market Exclusive - Apr 6, 2017 Michael R. Bristow , insider of Arca Biopharma Inc  reportedly Sold 720 shares of the company's stock at an average price of 2.41 for a total transaction amount of $1,735.20 SEC Form."
p6
aS'Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial Business Wire  - Jan 18, 2017 WESTMINSTER, Colo.----ARCA biopharma, Inc. , a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that the&nbsp;...'
p7
aS'Insider Trading Activity Arca Biopharma Inc   Director Bought ... Market Exclusive - Mar 28, 2017 On 2/4/2014 Riley Mccormack, Major Shareholder, bought 1,000,000 with an average share price of $1.70 per share and the total transaction amounting to $1,700,000.00.'
p8
aS'ARCA biopharma Gains on Fast Track Status for Gencaro Zacks.com - Apr 14, 2015 ARCA biopharma, Inc. shares gained 13.4% after the company announced that it has received Fast Track designation from the FDA for its lead pipeline candidate, Gencaro.'
p9
aS'ARCA biopharma Announces $37 Million Private Placement Business Wire  - Jun 11, 2015 WESTMINSTER, Colo.----ARCA biopharma, Inc. , a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has entered into a securities purchase&nbsp;...'
p10
a.